PERSON
Pfizer Appoints Citi Analyst Andrew Baum as New Strategy Chief
Pfizer, Andrew Baum, Citi analyst, strategy chief, pharmaceutical industry, leadership change, strategic planning.
Novartis Invests $1 Billion in Acquisition of Radioligand Therapy Pioneer Mariana
Novartis, Mariana, radioligand therapy, cancer treatment, targeted therapy, precision medicine, billion-dollar acquisition, healthcare innovation.
Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity
Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.
X4 Pharmaceuticals’ Xolremdi Granted Approval for Treating Rare Immunodeficiency Disorder
X4 Pharmaceuticals, Xolremdi, approval, rare immunodeficiency disorder, WHIM syndrome, FDA, treatment, breakthrough therapy, CXCR4 antagonist.
Cigna’s Evernorth Pushes for Increased Humira Biosimilar Adoption
Cigna, Evernorth, Humira, biosimilars, healthcare, pharmacy services, cost savings, patient access, AbbVie
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Ozempic, Wegovy, drug prices, Senator Bernie Sanders, diabetes, obesity
AstraZeneca CEO Pascal Soriot’s Pay Rise Signals Succession Planning
AstraZeneca, Pascal Soriot, CEO, pay rise, succession planning, pharmaceutical industry, executive compensation.
Senator Sanders Investigates Skyrocketing Costs of Novo Nordisk’s Diabetes and Weight Loss Drugs
Senator Bernie Sanders, Novo Nordisk, diabetes, weight loss, drug prices, Novos Ozempic, Wegovy, investigation, healthcare costs, affordability
Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment
Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.
Novartis Appoints Ex-Bristol Myers CEO Giovanni Caforio as Chair: Potential for Future M&A Deals?
Novartis, Bristol Myers, Giovanni Caforio, Chair, Mergers and Acquisitions (M&A), Pharmaceutical Industry, Corporate Strategy, Leadership Change.